C 반응성 단백질 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 검사 유형별, 탐지 범위별, 질환 영역별, 최종 용도 산업별, 지역별, 경쟁(2021-2031년)

The Global C-reactive Protein Testing Market is projected to expand from USD 1.95 Billion in 2025 to USD 2.21 Billion by 2031, reflecting a CAGR of 2.11%. This diagnostic method, which quantifies C-reactive protein in blood samples, serves as a vital biomarker for systemic inflammation, bacterial infections, and cardiovascular risks. Growth is largely fueled by the rising incidence of chronic cardiovascular and inflammatory conditions that require ongoing patient monitoring and risk assessment. For instance, the American Heart Association reported that the global prevalence of cardiovascular disease reached approximately 612 million cases in 2025, highlighting the critical need for inflammatory markers. Additionally, the market is bolstered by an aging global population and a noticeable transition toward decentralized point-of-care testing solutions.

However, a major obstacle hindering market progress is the strict regulatory landscape combined with variable reimbursement policies across different regions. These administrative and economic hurdles often postpone the commercial authorization of novel testing platforms and restrict the financial viability of high-sensitivity diagnostic tools for healthcare providers. Consequently, these barriers limit the broader adoption and market penetration of advanced diagnostic solutions.

Market Driver

The escalating burden of chronic and inflammatory diseases acts as a primary engine for the Global C-reactive Protein Testing Market's development. Because systemic inflammation is a core component of cardiovascular diseases, diabetes, and autoimmune conditions, the clinical imperative for precise biomarkers to track disease progression has grown stronger. Medical professionals are increasingly utilizing C-reactive protein assays for early inflammation detection and effective therapy management, especially considering the vast impact of noncommunicable diseases. According to the World Health Organization's April 2024 fact sheet, noncommunicable diseases are responsible for 41 million deaths annually, accounting for 74% of global mortality, a statistic that underscores the necessity for rigorous diagnostic protocols and high demand for testing in both hospital and outpatient environments.

Simultaneously, the market is being shaped by the growing integration of point-of-care testing platforms, which decentralize diagnostic processes and facilitate swift clinical decision-making. These portable devices enable immediate protein level analysis outside of traditional laboratories, aiding in the differentiation between bacterial and viral infections and helping to minimize inappropriate antibiotic use. Major manufacturers are expanding their capabilities to address this shift towards decentralized care; for example, Abbott reported worldwide Diagnostics sales of USD 2.4 billion in their October 2024 results, highlighting the persistent demand for accessible diagnostic tools. Furthermore, demographic trends identified by the United Nations in 2024 indicate a significant rise in the global population aged 65 and older, increasing the patient base susceptible to inflammatory conditions and driving the need for regular health monitoring.

Market Challenge

Growth in the Global C-reactive Protein Testing Market is heavily constrained by a rigorous regulatory environment and inconsistent reimbursement strategies. Manufacturers must navigate complex and shifting compliance standards that prolong approval processes and escalate development expenses. This regulatory pressure forces companies to divert crucial capital away from the research and development of high-sensitivity assays, thereby delaying the commercial launch of advanced diagnostic innovations. As a result, the uncertainty surrounding approval pathways often deters companies from introducing new products in major markets, ultimately limiting the diagnostic options available to healthcare providers for effective patient monitoring.

In addition to regulatory hurdles, ambiguous reimbursement frameworks introduce financial risks that inhibit the uptake of these tests. Clinical laboratories are frequently hesitant to invest in modern diagnostic platforms lacking clear payment assurances, a factor that directly impedes market penetration. Data from MedTech Europe in 2025 highlighted the severity of this issue, revealing that certification costs under the In Vitro Diagnostic Regulation surged by up to 100% compared to earlier standards, prompting a 40% reduction in large manufacturers choosing the European Union as their primary launch region. This demonstrates how administrative and economic impediments actively suppress the market's potential for broader expansion.

Market Trends

The utilization of CRP testing within Antimicrobial Stewardship Programs is fundamentally transforming market demand as healthcare systems incorporate diagnostic algorithms into national strategies against drug resistance. Institutional protocols increasingly require CRP screening before antibiotic administration to ensure alignment with global stewardship objectives, thereby elevating the assay from a standard diagnostic tool to a vital element of regulatory compliance. This shift drives the acquisition of rapid testing platforms as critical infrastructure for public health adherence, particularly for validating treatment choices in respiratory infections. As noted in an Abbott article from January 2024, utilizing C-reactive protein point-of-care testing alongside communication training has been demonstrated to decrease antibiotic prescribing by over 60%.

Concurrently, the widespread application of High-Sensitivity CRP (hs-CRP) for cardiovascular risk stratification is broadening the test's scope from monitoring acute inflammation to long-term preventative cardiology. Clinicians are placing greater emphasis on hs-CRP to detect residual inflammatory risks in asymptomatic individuals, enabling early intervention strategies that complement traditional lipid management. This trend is gaining momentum as fresh clinical evidence confirms the biomarker's ability to predict future adverse events over long periods, encouraging providers to add these assays to routine screenings. For instance, research presented at the European Society of Cardiology Congress in August 2024 indicated that women with elevated C-reactive protein levels faced a 70% higher risk of heart disease compared to those with the lowest levels.

Key Market Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher Corp
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott Laboratories Inc.
• Merck KGaAA
• Zoetis Inc.
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.

Report Scope

In this report, the Global C-reactive Protein Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

C-reactive Protein Testing Market, By Assay Type

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

C-reactive Protein Testing Market, By Detection Range

• hs-CRP
• Conventional CRP
• cCRP

C-reactive Protein Testing Market, By Disease Area

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

C-reactive Protein Testing Market, By End-Use Industry

• Hospitals & Clinics
• Laboratories
• Assisted Living Healthcare Facilities
• Homecare
• Others

C-reactive Protein Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global C-reactive Protein Testing Market.

Available Customizations:

Global C-reactive Protein Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global C-reactive Protein Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others)
  • 5.2.2. By Detection Range (hs-CRP, Conventional CRP, cCRP)
  • 5.2.3. By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others)
  • 5.2.4. By End-Use Industry (Hospitals & Clinics, Laboratories, Assisted Living Healthcare Facilities, Homecare, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America C-reactive Protein Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Assay Type
  • 6.2.2. By Detection Range
  • 6.2.3. By Disease Area
  • 6.2.4. By End-Use Industry
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States C-reactive Protein Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Assay Type
      • 6.3.1.2.2. By Detection Range
      • 6.3.1.2.3. By Disease Area
      • 6.3.1.2.4. By End-Use Industry
  • 6.3.2. Canada C-reactive Protein Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Assay Type
      • 6.3.2.2.2. By Detection Range
      • 6.3.2.2.3. By Disease Area
      • 6.3.2.2.4. By End-Use Industry
  • 6.3.3. Mexico C-reactive Protein Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Assay Type
      • 6.3.3.2.2. By Detection Range
      • 6.3.3.2.3. By Disease Area
      • 6.3.3.2.4. By End-Use Industry

7. Europe C-reactive Protein Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Assay Type
  • 7.2.2. By Detection Range
  • 7.2.3. By Disease Area
  • 7.2.4. By End-Use Industry
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany C-reactive Protein Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Assay Type
      • 7.3.1.2.2. By Detection Range
      • 7.3.1.2.3. By Disease Area
      • 7.3.1.2.4. By End-Use Industry
  • 7.3.2. France C-reactive Protein Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Assay Type
      • 7.3.2.2.2. By Detection Range
      • 7.3.2.2.3. By Disease Area
      • 7.3.2.2.4. By End-Use Industry
  • 7.3.3. United Kingdom C-reactive Protein Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Assay Type
      • 7.3.3.2.2. By Detection Range
      • 7.3.3.2.3. By Disease Area
      • 7.3.3.2.4. By End-Use Industry
  • 7.3.4. Italy C-reactive Protein Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Assay Type
      • 7.3.4.2.2. By Detection Range
      • 7.3.4.2.3. By Disease Area
      • 7.3.4.2.4. By End-Use Industry
  • 7.3.5. Spain C-reactive Protein Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Assay Type
      • 7.3.5.2.2. By Detection Range
      • 7.3.5.2.3. By Disease Area
      • 7.3.5.2.4. By End-Use Industry

8. Asia Pacific C-reactive Protein Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Assay Type
  • 8.2.2. By Detection Range
  • 8.2.3. By Disease Area
  • 8.2.4. By End-Use Industry
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China C-reactive Protein Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Assay Type
      • 8.3.1.2.2. By Detection Range
      • 8.3.1.2.3. By Disease Area
      • 8.3.1.2.4. By End-Use Industry
  • 8.3.2. India C-reactive Protein Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Assay Type
      • 8.3.2.2.2. By Detection Range
      • 8.3.2.2.3. By Disease Area
      • 8.3.2.2.4. By End-Use Industry
  • 8.3.3. Japan C-reactive Protein Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Assay Type
      • 8.3.3.2.2. By Detection Range
      • 8.3.3.2.3. By Disease Area
      • 8.3.3.2.4. By End-Use Industry
  • 8.3.4. South Korea C-reactive Protein Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Assay Type
      • 8.3.4.2.2. By Detection Range
      • 8.3.4.2.3. By Disease Area
      • 8.3.4.2.4. By End-Use Industry
  • 8.3.5. Australia C-reactive Protein Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Assay Type
      • 8.3.5.2.2. By Detection Range
      • 8.3.5.2.3. By Disease Area
      • 8.3.5.2.4. By End-Use Industry

9. Middle East & Africa C-reactive Protein Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Assay Type
  • 9.2.2. By Detection Range
  • 9.2.3. By Disease Area
  • 9.2.4. By End-Use Industry
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia C-reactive Protein Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Assay Type
      • 9.3.1.2.2. By Detection Range
      • 9.3.1.2.3. By Disease Area
      • 9.3.1.2.4. By End-Use Industry
  • 9.3.2. UAE C-reactive Protein Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Assay Type
      • 9.3.2.2.2. By Detection Range
      • 9.3.2.2.3. By Disease Area
      • 9.3.2.2.4. By End-Use Industry
  • 9.3.3. South Africa C-reactive Protein Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Assay Type
      • 9.3.3.2.2. By Detection Range
      • 9.3.3.2.3. By Disease Area
      • 9.3.3.2.4. By End-Use Industry

10. South America C-reactive Protein Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Assay Type
  • 10.2.2. By Detection Range
  • 10.2.3. By Disease Area
  • 10.2.4. By End-Use Industry
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil C-reactive Protein Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Assay Type
      • 10.3.1.2.2. By Detection Range
      • 10.3.1.2.3. By Disease Area
      • 10.3.1.2.4. By End-Use Industry
  • 10.3.2. Colombia C-reactive Protein Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Assay Type
      • 10.3.2.2.2. By Detection Range
      • 10.3.2.2.3. By Disease Area
      • 10.3.2.2.4. By End-Use Industry
  • 10.3.3. Argentina C-reactive Protein Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Assay Type
      • 10.3.3.2.2. By Detection Range
      • 10.3.3.2.3. By Disease Area
      • 10.3.3.2.4. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global C-reactive Protein Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. F. Hoffmann-La Roche Ltd.
• 15.3. Danaher Corp
• 15.4. Quest Diagnostics
• 15.5. Siemens Healthineers AG
• 15.6. Abbott Laboratories Inc.
• 15.7. Merck KGaAA
• 15.8. Zoetis Inc.
• 15.9. Ortho Clinical Diagnostics
• 15.10. Getein Biotech, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer